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Reversible changes in pancreatic islet structure and
function produced by elevated blood glucose
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Diabetes is characterized by hyperglycaemia due to impaired insulin secretion and aberrant
glucagon secretion resulting from changes in pancreatic islet cell function and/or mass. The
extent to which hyperglycaemia per se underlies these alterations remains poorly understood.
Here we show that b-cell-specific expression of a human activating KATP channel mutation in
adult mice leads to rapid diabetes and marked alterations in islet morphology, ultrastructure
and gene expression. Chronic hyperglycaemia is associated with a dramatic reduction
in insulin-positive cells and an increase in glucagon-positive cells in islets, without alterations
in cell turnover. Furthermore, some b-cells begin expressing glucagon, whilst retaining many
b-cell characteristics. Hyperglycaemia, rather than KATP channel activation, underlies these
changes, as they are prevented by insulin therapy and fully reversed by sulphonylureas. Our
data suggest that many changes in islet structure and function associated with diabetes are
attributable to hyperglycaemia alone and are reversed when blood glucose is normalized.
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D
iabetes mellitus currently affects over 330 million people
worldwide. It is a heterogeneous disorder with multiple
aetiologies, but all result in a persistently elevated blood
glucose concentration as a consequence of insufficient insulin
release by pancreatic b-cells1. In type-1 diabetes, the insulin-
producing b-cells are destroyed and patients require lifelong
treatment with exogenous insulin. In type-2 diabetes mellitus
(T2DM), the b-cells largely remain, but they fail to release
sufficient insulin to maintain normoglycaemia. Both reduced
b-cell mass and impaired b-cell function have been proposed to
underlie the defective insulin secretion, but their relative
contribution is debated2–4. There are also a number of rare
monogenic forms of diabetes that present either at birth (neonatal
diabetes) or in young adult life (maturity onset diabetes of the
young)1. The primary problem in almost all of these genetic
disorders is insufficient insulin secretion. In addition, glucagon
secretion from pancreatic a-cells is usually disturbed.
The extent to which hyperglycaemia per se underlies, or
exacerbates, alterations in b-cell and a-cell function and/or mass
in diabetes remains poorly understood. Numerous studies have
examined the effect of hyperglycaemia on isolated islets, b-cells or
b-cell lines5. These have concluded that culture in high glucose
(420mM) for several days leads to a reduction in insulin
content, impaired insulin secretion and multiple changes in gene
expression. However, such studies have the limitation that
changes in gene expression may occur as a consequence of
in vitro culture. The effects of hyperglycaemia have also been
explored using various mouse models of diabetes6. Most of these,
however, suffer from the disadvantage that the insulin secretory
defect cannot be reversed, either because the diabetes is genetic or
is artificially induced by b-cell ablation. Furthermore, the
diabetogenic gene(s) may be unknown, is usually expressed in
all tissues and may be associated with insulin resistance and/or
obesity. This makes dissecting the effect of hyperglycaemia per se
on pancreatic islet cells in vivo difficult. In this respect, a means of
selectively and reversibly switching off insulin secretion would be
advantageous. One way to do so is by manipulating ATP-sensitive
Kþ (KATP) channel activity.
The prominent role of the KATP channel in regulating glucose-
stimulated insulin secretion is well established7,8. These channels
are regulated by metabolically generated ATP and thereby link
changes in blood glucose concentration to insulin release. When
KATP channels are open, as at low plasma glucose levels, Ca2þ
influx and insulin secretion are prevented, switching off insulin
release. A rise in blood glucose elevates intracellular ATP, closing
KATP channels and leading to membrane depolarization, b-cell
electrical activity, Ca2þ influx and insulin release. The crucial
role of KATP channel function in controlling blood glucose is
illustrated by the fact that mutations in KATP channel genes can
cause aberrant insulin secretion. For example, gain-of-function
mutations in either the Kir6.2 or SUR1 subunits of the KATP
channel are a common cause of neonatal diabetes, a rare genetic
form of the disease that presents within the first 6 months
of life9–11. All these mutations impair the ability of metabolically
generated ATP to close the channel, and thereby prevent insulin
secretion. Mice that express activating KATP channel mutations
selectively in their pancreatic b-cells recapitulate many of the
characteristics of neonatal diabetes12–14: in particular, they
display hyperglycaemia and hypoinsulinaemia in the absence of
obesity and insulin resistance.
Here we use a transgenic mouse that expresses a human
neonatal diabetes mutation (Kir6.2-V59M) specifically in
b-cells12 to investigate the effects of chronic hyperglycaemia on
islet cell structure and function. In this mouse model, insulin
secretion is rapidly switched off following KATP channel
activation but can be restored by treatment with sulphonylurea
(SU) drugs, which are specific KATP channel blockers. This
allowed us to assess the effects of reversible hyperglycaemia on
pancreatic islet cells. Our results suggest that many of the changes
in islet structure and function associated with diabetes are
attributable to hyperglycaemia, and can be reversed by
normalization of blood glucose. These data have implications
for understanding the aetiology and treatment of diabetes.
Results
Expression of Kir6.2-V59M in b-cells rapidly induces diabetes.
We generated an inducible mouse model selectively expressing a
gain-of-function KATP channel mutation (Kir6.2-V59M) in pan-
creatic b-cells (bV59M mice). Expression was induced at 12
weeks of age by tamoxifen injection. This resulted in a rapid rise
in the blood glucose concentration of free-fed mice that exceeded
20mM within 2 days and was sustained throughout the next 4
weeks (Fig. 1a). Free-fed (Supplementary Fig. 1a) and fasted
(Supplementary Fig. 1b) plasma insulin levels were significantly
reduced (B60%) by Kir6.2-V59M gene expression. Plasma glu-
cagon levels did not change (Supplementary Fig. 1c,d).
We examined the effects of insulin or glibenclamide therapy
using slow-release pellets implanted subcutaneously once blood
glucose had risen above 20mM. Free-fed blood glucose levels
were not significantly different in bV59M mice implanted with a
placebo pellet (containing no drug) from those that did not
receive a pellet (Fig. 1a).
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Figure 1 | Gene induction results in rapid diabetes that is normalized
by insulin and SU therapy. (a) Blood glucose levels for 12-week-old
bV59M (open circle, black star) and control (black circle, n¼41) mice.
Mice were injected with tamoxifen (Tx) as indicated by the arrow to induce
Kir6.2-V59M expression. Some Tx-injected mice were subsequently
implanted with a subcutaneous slow-release placebo pellet at time zero
(black star, n¼ 35), whereas others were not (open circle, n¼ 31).
(b,c) Blood glucose levels measured in bV59M mice injected with Tx
(arrow) and subsequently implanted (arrow) with an insulin pellet (b; open
square, n¼ 6) or glibenclamide pellet (c; open triangle, n¼ 19). Control
mice (black circle) and Tx-induced untreated bV59M mice (open circle) are
the same data as in Fig. 1a. (d) bV59M mice injected with Tx (arrow) and
subsequently implanted (arrow) with a glibenclamide pellet (Glib) after
4 weeks of diabetes (open diamond, n¼ 6). Control littermates (black
circle, n¼6) were sham injected with Tx. Data are mean values±s.e.m.
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Implantation of an insulin pellet (releasing 0.2–0.3U per day)
caused a rapid fall in blood glucose from 20.3±1.4mM (n¼ 6)
on the day of implantation to 8.2±3.2mM 2 days later (Fig. 1b).
However, insulin therapy failed to maintain normoglycaemia
consistently throughout the 4-week period, and sporadic episodes
of hypoglycaemia (o2mM) and hyperglycaemia (420mM)
were common.
Glycaemic control was greatly improved in mice treated with
glibenclamide pellets (Fig. 1c). However, the dose needed to
control the blood glucose level varied with the duration of
hyperglycaemia. When glibenclamide was administered immedi-
ately following a rise in blood glucose to 420mM, a dose of
17mg kg 1 per day was sufficient to produce normoglycaemia
(Fig. 1c), whereas a dose of 34–95mg kg 1 per day was necessary
to normalize glycaemia in mice that had been diabetic for 4 weeks
(Fig. 1d).
Glibenclamide therapy caused a rapid fall in free-fed blood
glucose: 2 days after drug implantation, glucose concentrations
were 4.6±0.2mM (n¼ 19; Fig. 1c) in mice previously exposed to
24 h of hyperglycaemia and 4.6±0.4mM (n¼ 6; Fig. 1d) in those
exposed to 4 weeks of hyperglycaemia. These values are close to
those measured in the same animals before gene induction
(5.6±0.1mM; n¼ 25) or in control mice (5.9±0.2mM; n¼ 41).
Blood glucose levels were stable throughout the 4 weeks of
glibenclamide treatment.
Effect of long-term hyperglycaemia on islet morphology.
Hyperglycaemia for 4 weeks led to marked changes in islet
morphology. There was a dramatic decrease in insulin-positive
(insþ ) cells and a concomitant increase in glucagon-positive
(gluþ ) cells, which were no longer confined to the mantle but
populated the core of the islet (compare Fig. 2c,d with Fig. 2a,b).
Quantitative analysis revealed a marked reduction (B70%) in
the area of the islet staining for insulin and an equivalent
increase in the area staining for glucagon (Fig. 3a,b). A reduction
in the percentage area of the pancreas staining for insulin
(a surrogate for b-cell mass) and an increase in the area staining
for glucagon was also observed (Fig. 3c,d). Chronic hypergly-
caemia did not produce a statistically significant change in the
percentage area of the pancreas occupied by islets (Supplementary
Fig. 2a) or in islet density (islet number per cm2 pancreas)
(Supplementary Fig. 2b,c).
Insulin therapy largely prevented the reduction in insulin
staining and increase in glucagon staining when data were
expressed relative to islet area (Fig. 2e,f and Fig. 3a,b) or per cm2
pancreas (Fig. 3c,d). Thus, the decline in insþ cells (and
corresponding increase in gluþ cells) is principally the result of
hyperglycaemia per se and not KATP channel hyperactivity.
Glibenclamide therapy also prevented the diabetes-induced
changes in insulin (Fig. 2g) and glucagon (Fig. 2h) staining, and
in the area of individual islets, or whole pancreas, composed of
insþ and gluþ cells (Fig. 3a–d). Drug treatment was slightly
more effective than insulin, perhaps because it produced more
stable control of blood glucose (compare Fig. 1b and c).
Remarkably, 4 weeks of glibenclamide therapy almost fully
reversed the histological changes produced by 4 weeks of
hyperglycaemia. Insulin staining was observed throughout the
islet and glucagon staining was once more confined to the mantle
(Fig. 2i,j). The islet area (Fig. 3a,b) and pancreas area (Fig. 3c,d)
occupied by insþ or gluþ cells were restored to levels similar to
those found in control mice.
Consistent with the decrease in the percentage of the islet area
showing insulin immunoreactivity, and the concomitant increase
in glucagon immunoreactivity, insulin messenger RNA and
insulin content were reduced (Fig. 3e,g), and preproglucagon
mRNA and glucagon content were enhanced (Fig. 3f,h), in islets
isolated from mice that had been hyperglycaemic for 4 weeks,
when compared with control animals.
Effects of hyperglycaemia on islet cell ultrastructure. Exposure
to chronic diabetes resulted in striking changes in b-cell ultra-
structure. Compared with control littermates (Fig. 4a), the
number of insulin granules was considerably reduced in mice
exposed to diabetes for 4 weeks (Fig. 4b). Surprisingly, in many
b-cells, large areas of cytoplasm were filled with a homogeneous
unstructured substance that displaced the intracellular organelles.
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Figure 2 | Chronic hyperglycaemia alters insulin and glucagon
immunostaining in pancreatic islets. Representative serial sections of
mouse pancreas immunostained for insulin (left) or glucagon (right) using
DAB (brown). Control mouse pancreas (a,b). bV59M mouse pancreas 4
weeks after implantation with a placebo (c,d), insulin (e,f), or glibenclamide
(g,h) pellet. (i,j) Islets from bV59M mice exposed to 4 weeks of
hyperglycaemia and then 4 weeks of glibenclamide therapy (n¼4). Results
are representative of four (a–d,i–j) or three (g,h) mice. Scale bar, 50mm
(applies to all panels).
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms5639 ARTICLE
NATURE COMMUNICATIONS | 5:4639 | DOI: 10.1038/ncomms5639 |www.nature.com/naturecommunications 3
& 2014 Macmillan Publishers Limited. All rights reserved.
The shape of the nucleus was occasionally distorted, but there was
no indication of any apoptotic changes. No morphological signs
of cellular stress were detected: the mitochondria and endo-
plasmic reticulum were not swollen and appeared normal. Fur-
thermore, transcript levels of the endoplasmic reticulum (ER)
stress markers Chop and spliced Xbp1 were unaltered in islets
isolated from 4-week diabetic mice compared with controls
(Supplementary Fig. 3a). The ultrastructural changes were specific
to b-cells, and not observed in adjacent a-cells or d-cells
(Supplementary Fig. 3b).
No effect on b-cell ultrastructure was observed following
Kir6.2-V59M gene induction and only 24 h of hyperglycaemia
and b-cells remained well granulated (Supplementary Fig. 3c).
This supports the view that KATP channel activation acutely
inhibits insulin release by preventing b-cell electrical activity12,14
rather by affecting insulin content.
Immediate insulin therapy prevented the ultrastuctural changes
associated with diabetes (Fig. 4c). Even more remarkably, the
ultrastructural changes associated with 4 weeks of diabetes were
completely reversed after 4 weeks of glibenclamide therapy
(Fig. 4d). In glibenclamide-treated islets, the majority of b-cells
were densely packed with insulin granules, which had a size and
morphology similar to those observed in control animals. Taken
together, the data indicate that b-cell ultrastructural changes
are due to hyperglycaemia and/or hypoinsulinaemia and—
importantly—are reversible on restoration of euglycaemia.
C P Ins Glib D + Glib
0
25
50
75
100
***
*** ***
***
In
s+
 
a
re
a
(%
 of
 is
let
 ar
ea
)
C P Ins Glib D + Glib
0
1
2
3
4
5
*
**
%
 In
s+
 
a
re
a
(pe
r c
m2
 
pa
nc
re
as
)
C 4wk
0.0
0.2
0.4
0.6
0.8
1.0
*
In
su
lin
 
m
R
N
A 
re
la
tiv
e
e
xp
re
ss
io
n 
(a.
u.)
C 4wk
0
50
100
150
200
*
In
su
lin
 c
on
te
nt
(ng
/is
let
)
C P Ins Glib D + Glib
0
25
50
75
100
*** ***
***
***
G
lu
+
 
a
re
a
 (%
 of
 is
let
 ar
ea
)
C P Ins Glib D + Glib
0.0
0.5
1.0
1.5
2.0
***
**
**
%
 G
lu
+
 
a
re
a
(pe
r c
m2
 
pa
nc
re
as
)
C 4wk
0.0
0.2
0.4
0.6
0.8
1.0
*
Pr
ep
ro
gl
uc
ag
on
 
m
R
N
A
re
la
tiv
e 
ex
pr
es
sio
n 
(a.
u.)
 
C 4wk
0
1
2
3
4
*
G
lu
ca
go
n 
co
nt
en
t
(ng
/is
let
)
Figure 3 | Effects of chronic hyperglycaemia on insulin and glucagon
levels. Mean islet cross-sectional area immunostaining for insulin (a,c) or
glucagon (b,d), expressed either as a percentage of the total islet cross-
sectional area (a,b) or per cm2 of pancreas (c,d). Once plasma glucose
exceeded 20mM, bV59M mice were treated for 4 weeks with placebo (P),
insulin (Ins) or glibenclamide (Glib); or, following 4 weeks of no therapy,
with 4 weeks of glibenclamide (DþGlib). Data are mean±s.e.m. of three
to six mice per genotype (five sections per mouse, 100mm apart).
(*Po0.05; **Po0.01, ***Po0.001 compared with placebo (P); one-way
analysis of variance followed by post-hoc Bonferroni test). Insulin (e) and
preproglucagon (f) mRNA levels determined by qPCR in islets isolated from
control (C, black bars) and 4-week-diabetic (4wk, white bars) bV59M mice
(n¼6–7 per genotype). Insulin (g) and glucagon (h) protein content of
islets determined by radioimmunoassay from control (C) and 4-week-
diabetic (4wk) bV59M mice (*Po0.05; Mann–Whitney test; n¼6–7 per
genotype). Data are mean values±s.e.m.
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Figure 4 | Chronic hyperglycaemia reversibly alters b-cell ultrastructure.
Representative electron micrographs of pancreatic sections from control
mice (a), bV59M mice exposed to hyperglycaemia for 4 weeks (b),
bV59M mice treated with insulin for 4 weeks (c) and bV59M mice that
were hyperglycaemic for 4 weeks and then treated with glibenclamide for
4 weeks (d). Scale bar, 2mm (refers to all panels). Images are
representative of: a, 9 mice/9 islets/150 b-cells; b, 3 mice/9 islets/134
b-cells; c, 2 mice/3 islets/100 b-cells; d, 3 mice/3 islets/105 b-cells.
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Effect of chronic hyperglycaemia on islet cell identity. We next
investigated the mechanism(s) underlying the alterations in islet
cell composition in chronically diabetic bV59M mice. We first
explored whether they were caused by changes in cell turnover.
Because of marked b-cell degranulation in bV59M mice, we used
electron microscopy to identify b-cells unequivocally and nuclear
morphology (condensed chromatin) as a measure of apoptosis.
We found 3.7% of b-cells (that is, cells containing typical insulin
granules) from 4-week diabetic bV59M mice had apoptotic nuclei
(Supplementary Fig. 3d); similar numbers were found in control
islets (4.0%). Cell proliferation, determined by Ki67 positivity,
was also unchanged in gluþ cells (Supplementary Fig. 4a,b).
Thus, the changes we observe are unlikely to be due to b-cell
death or a-cell proliferation.
We also examined transcript levels of green fluorescent
protein (GFP), which is located downstream of Kir6.2-V59M in
the transgene cassette and thus serves as a marker of gene
induction12. A 430-fold increase in islet GFP mRNA was
observed 24 h after establishment of a free-fed blood glucose of
420mM by gene induction (Fig. 5a). Islet GFP mRNA levels
were unchanged after 4 weeks of chronic hyperglycaemia
(Fig. 5a), despite the reduction in islet insulin immunostaining
(Fig. 2), insulin mRNA (B50%, Fig. 3e) and insulin content
(B70%, Fig. 3g). This provides further support for the idea that
the reduction in insþ cells we observe is not due to b-cell death.
Chronic hyperglycaemia was associated with a B20-fold
increase in cells positive for both insulin and glucagon
(insþ /gluþ cells) in islets from 4-week-diabetic bV59M mice
(Fig. 5b,c). However, in mice treated with insulin for 4 weeks
immediately after establishment of diabetes, or treated with
glibenclamide following 4 weeks of hyperglycaemia, the number
of insþ /gluþ cells was not significantly different from control
animals (Fig. 5b). This argues the increase in insþ /gluþ cells is
caused by hyperglycaemia/hypoinsulinaemia and is reversed
when blood glucose is normalized.
We used lineage tracing to test whether b-cells start to express
glucagon when exposed to chronic hyperglycaemia. Although
GFP was located downstream of Kir6.2-V59M in the transgene
cassette, expression was too weak to be visualized by immuno-
fluorescence. Thus, a Rosa26RFP reporter was crossed into RIPII-
CreER mice with (bV59M-RFP mice) or without (b-RFP control
mice) the floxed Kir6.2-V59M transgene, to label all b-cells and
their progeny with red fluorescent protein (RFP) after tamoxifen
injection (Fig. 6a and Supplementary Fig. 5a,b).
In b-RFP mice, 67% of insþ cells labelled with RFP (this
indicates the recombination frequency). In bV59M-RFP mice
exposed to chronic hyperglycaemia for 4 weeks, 7% of RFPþ cells
(that is, cells of b-cell lineage) contained both insulin and
glucagon, and 8% expressed glucagon alone (Fig. 6b and
Supplementary Fig. 5c). Approximately 60% of RFPþ cells
expressed insulin and 24% did not detectably express either
insulin or glucagon. Fluorescence-assisted cell (FAC) sorting by
RFP fluorescence (Supplementary Fig. 5a,b) revealed RFPþ cells
from diabetic bV59M-RFP mice had more preproglucagon
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Figure 5 | Insulin/glucagon double-positive cells are reversibly increased by hyperglycaemia. (a). GFP mRNA levels determined by qPCR in islets
isolated from control mice and bV59M mice 24-h (24 h) and 4 weeks (4wk) after diabetes onset. Data are mean values±s.e.m., n¼4 per genotype.
(*Po0.05; one-way analysis of variance (ANOVA) followed by post-hoc Bonferroni test). (b) Dual insþ/gluþ cells expressed as a percentage
of the total number of insþ cells. Control islets (C). Islets from bV59M mice implanted with placebo (P) or insulin (Ins) for 4 weeks, or treated for
4 weeks with glibenclamide after 4 weeks of hyperglycaemia (PþGlib). Data are mean values±s.e.m., n¼ 2,600–7,700 insþ cells; n¼ 92–127 islets;
n¼ 3–4 mice per genotype. (*Po0.05 compared with placebo (P); one-way ANOVA followed by post-hoc Bonferroni test). (c) Representative example of
immunofluorescence staining for insulin (green), glucagon (pink), DAPI (40,6-diamidino-2-phenylindole; blue) and merged data (white) in control islets
and 4-week bV59M diabetic islets. White arrowheads indicate cells positive for both insulin and glucagon. Scale bars, 50mm control; 10mm 4-week
bV59M diabetic islets.
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mRNA (Fig. 6c) and glucagon protein (Fig. 6d), and less insulin
content (Supplementary Fig. 5d), than b-RFP littermate controls.
No significant change in glucagon content was observed in RFP
cells (Supplementary Fig. 5e).
Expression of several b-cell (Pdx-1, MafA, Nkx6.1 and Glut2)
and a-cell (Arx, Pax6 and MafB) markers was examined to
determine whether the molecular identity of islet cells was altered
by exposure to chronic hyperglycaemia. Immunofluorescence
microscopy of intact islets from 4-week-diabetic bV59M mice
identified expression of Pdx-1 (Fig. 7a), Glut2 (Fig. 7b) and MafA
(Fig. 7c) in insþ cells. Insþ /gluþ cells retained expression of
Pdx-1 and Glut2, but also expressed MafB (Fig. 7d). All gluþ cells
expressed MafB but a few also contained Pdx1. Nkx6.1 protein
was undetectable by immunofluorescence in 4-week diabetic islets
(compare Supplementary Fig. 6a with 6b). Quantitative PCR
(qPCR) analysis revealed reduced expression of the b-cell markers
Pdx-1 (P¼ 0.05; Mann-Whitney test), Nkx6.1, MafA and Glut2 in
intact islets from 4-week-diabetic bV59M mice (Fig. 7e).
Although the a-cell marker MafB appeared elevated, Arx and
Pax6 mRNA levels were unchanged (Fig. 7e).
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Figure 6 | Chronic hyperglycaemia induces glucagon expression in b-cells. (a) Schematic illustrating how Rip-CreERþ /þ (i), RosaRFP/ (ii) and
RosaV59M/ (iii) were used to generate RosaRFP/V59M mice (bV59M-RFP mice). b-Cells were selectively and irreversibly labelled following tamoxifen
injection, by crossing an inducible rat insulin promoter Cre line (i; b) with a floxed tdRFP reporter line in which tdRFP expression was driven by the
endogenous ROSA promoter (ii; RFP). These b-RFP control mice were then crossed with an inducible Kir6.2-V59M line (iii; V59M) to create bV59M-RFP
mice (iv). (b) Representative examples of immunofluorescence staining for insulin (green), glucagon (pink) and RFP (red) in control (top panel, b-RFP) and
4-week-diabetic bV59M-RFP (middle and bottom panels) isolated islet cells. White arrows, RFPþ/gluþ cells. White arrowhead, RFPþ/gluþ/insþ cell.
Scale bar, 10mm. (c,d) Islet cells from b-RFP and 4-week-diabetic bV59M-RFP mice were FAC-sorted into RFPþ and RFP populations, and analysed for
preproglucagon mRNA by qPCR (c) and glucagon protein (d); n¼4 mice per genotype. Data are mean values±s.e.m. *Po0.05; Mann–Whitney test.
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In contrast to what was observed in islets, mRNA levels of
Nkx6.1, MafA and Glut2 were unaltered in FAC-sorted RFPþ
b-cells (Fig. 7f). The difference between the effect of diabetes on
mRNA expression in islets and FAC-purified RFPþ b-cells is
probably due to loss of a specific b-cell subpopulation during
FAC sorting: B30% fewer RFPþ b-cells were FAC sorted from
4-week diabetic mice than from b-RFP mice. It is possible that the
absent cells represent b-cells with large areas of unstructured
cytoplasm (identified in electron microscopy), which may be
more fragile and thus do not survive FAC sorting.
Expression of the a-cell transcription factors MafA and Arx
was increased in RFPþ FAC-sorted b-cells (Fig. 7f), which
explains the elevated glucagon content. Taken together, the data
confirm that cells with a b-cell lineage express glucagon in
response to chronic hyperglycaemia by increasing expression of
a-cell transcription factors. In addition, the islet progenitor cell
marker Ngn3 was elevated in both islets (Supplementary Fig. 6b)
and FAC-sorted RFPþ b-cells from 4-week-diabetic bV59M
mice (Supplementary Fig. 6c).
We also assessed the electrophysiological fingerprint of islet
cells from control and bV59M mice following 4 weeks of diabetes.
All cells were identified by immunolabelling for insulin and
glucagon after patch clamping. In bV59M mice, the Cre-lox
approach restricts expression of the mutant Kir6.2 subunit to cells
expressing insulin at the time of induction. As the Kir6.2-V59M
mutation markedly decreases KATP channel inhibition by ATP,
and thereby increases current amplitude12,15, large amplitude
KATP currents also serve as a lineage marker for b-cells. Cell-
attached KATP currents from control b-cells were small (5±2 pA;
n¼ 27), due to inhibition by intracellular ATP. In contrast, insþ
cells from bV59M mice hadB10-fold larger currents (49±6 pA;
n¼ 48). Large on-cell KATP currents were also recorded from
insþ /gluþ cells, and even from a number of cells that expressed
glucagon alone (Fig. 8a,b).
Marked differences in the voltage-dependence of Naþ -current
inactivation were observed between control mouse b- and a-cells
in intact freshly isolated islets, with half-maximal inactivation
(V0.5) occurring at  103±1mV (n¼ 5) and  75±1mV
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Figure 7 | Effects of hyperglycaemia on islet cell transcription factors and transporters. (a–d) Representative examples of immunofluorescence
staining for (red) Pdx-1 (a), Glut2 (b), MafA (c) or MafB (d) in a 4-week-diabetic bV59M islet. Insulin (green), glucagon (pink). (a) Insets show (upper)
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Whitney test).
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(n¼ 6), respectively (Fig. 8c). In insþ /gluþ cells (Fig. 8c,d), V0.5
was  117±2mV (n¼ 6; also measured in acutely isolated intact
islets): this is similar to control b-cells and provides further
evidence that insþ /gluþ cells derive from b-cells and retain
many b-cell properties.
Discussion
Our data demonstrate that expression of a human activating KATP
channel mutation in adult mouse b-cells leads to rapid diabetes
and marked alterations in islet morphology and ultrastructure.
Following 4 weeks of diabetes, islet insulin mRNA and protein
were dramatically reduced and glucagon mRNA and protein
increased. Importantly, the reduced insulin staining seen with
light microscopy did not equate with loss of b-cells, as evident
from electron microscopy. Some b-cells now expressed glucagon
and several a-cell transcription factors. However, they retained
b-cell characteristic proteins such as Glut2 and b-cell voltage-
gated Naþ channels. We show that hyperglycaemia, rather than
KATP channel activation per se, accounts for these changes, as they
can be prevented by insulin therapy. Strikingly, the effects of
chronic hyperglycaemia were also reversed when blood glucose
was normalized with the SU glibenclamide.
KATP channel activation led to a rapid and sustained rise in
blood glucose on gene induction. Treatment of bV59M mice with
either insulin or glibenclamide normalized blood glucose within
24 h of implementing therapy. Glibenclamide produced far more
stable control of plasma glucose than insulin (as it does in
patients with neonatal diabetes16). This may be because SUs exert
their effect indirectly by stimulating insulin release from
pancreatic b-cells17. KATP channel closure by SUs enables
additional mechanisms that enhance meal-induced insulin
secretion, such as the stimulatory effects of incretins (triggered
by the presence of food in the gut18) and the non-KATP-
dependent actions of glucose19. This should help reduce plasma
glucose fluctuations by directly linking insulin release to plasma
glucose concentrations and food ingestion. In contrast, insulin
therapy results in large spikes in blood glucose (as also seen in
bV59M mice), because an insulin dose sufficient to fully control
meal-stimulated spikes in plasma glucose cannot be used, as it
would produce hypoglycaemia at fasting plasma glucose levels.
Surprisingly, glibenclamide therapy rapidly normalized plasma
glucose levels, even after 4 weeks of diabetes. This agrees with
clinical data: many patients with neonatal diabetes have been
able to transfer to SU therapy, albeit with a very high dose,
even after years of insulin treatment18,20. Similar to patients with
many years of poor glycaemic control, bV59M mice required
higher drug doses following 4 weeks, rather than 2 days, of
hyperglycaemia. This may explain previous reports that
glibenclamide was unable to reverse established diabetes in
mice with a different activating KATP channel mutation, which
used a lower drug dose14,21.
Dramatic changes in insulin content, islet morphology and
b-cell ultrastructure were evident after 4 weeks of diabetes. There
was a marked reduction in islet cells staining for insulin,
consistent with the fall in islet insulin mRNA and protein levels.
Nevertheless, our data indicate that the loss of insulin
immunolabelling did not equate to loss of b-cell mass. This is
clear from the fact that many b-cells, albeit with very few insulin
granules, are observed at the ultrastructural level. The nuclear
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morphology of these b-cells also confirms they are not under-
going apoptosis. Furthermore, islet GFP mRNA levels do not
decrease with diabetes duration, as would be expected if b-cells
die (GFP serves as a b-cell lineage marker in bV59M mice). We
also found no change in apoptosis. Thus, our data argue that the
marked decrease in insulin staining we observe by immunohis-
tochemistry is not primarily due to b-cell loss but rather to a
dramatic reduction in insulin gene expression and insulin granule
density. The idea that reduced insulin content can give rise to the
fallacious impression of b-cell loss has also been suggested for
islets from patients with type T2D (ref. 22) and rodent models of
diabetes23.
In our mouse model, chronic hyperglycaemia not only led to a
remarkable reduction in insulin granule content but also to the
appearance of large areas of unstructured cytoplasm within
b-cells. We saw no morphological evidence of increased numbers
of lysosomes or autophagic bodies, and these cells did not show
any morphological signs of apoptotic death or ER stress.
Furthermore, the structural changes were fully reversible on
administration of glibenclamide; hence, they are not a sign of
permanent b-cell damage. Such dramatic changes in b-cell
ultrastructure have not been reported previously, either in mouse
models of diabetes or in islets from patients with T2DM. Thus, it
is possible they arise from a combination of hyperglycaemia/
hypoinsulinaemia and KATP channel activation.
Chronic hyperglycaemia was also associated with a marked
increase in preproglucagon mRNA and glucagon content, as well
as glucagon immunostaining, in b-cells. However, the increase in
glucagon immunostaining was significantly less than the reduc-
tion in insulin immunostaining, when normalized to pancreatic
area. This is consistent with the presence of many sparsely
granulated b-cells that do not contain sufficient insulin for
detection by conventional immunostaining. The low levels of
glucagon in b-cells (average B0.02 pg/RFPþ cell) compared
with pre-existing a-cells (B1.5 pg/RFP cell) (Fig. 6d and
Supplementary Fig. 5d) may explain why there was no obvious
change in plasma glucagon despite the increase in gluþ cells
and islet glucagon content. Furthermore, glucagon expressed
by b-cells is unlikely to be released due to the hyperpolarizing
effect of the KATP channel mutation.
Lineage tracing and electrophysiological recordings confirmed
that insþ /gluþ cells and a number of cells expressing glucagon
alone were of b-cell origin, as they expressed RFP and displayed
very large KATP currents (indicating they carried the Kir6.2-
V59M mutation). These cells also retained several b-cell
functional characteristics; they expressed the b-cell transcription
factor Pdx-1, the b-cell glucose transporter Glut2 and the voltage-
dependence of Naþ current inactivation was characteristic of
b-cell, not a-cell, Naþ channels24,25. However, the
a-cell transcription factors MafB and Arx were upregulated in
RFPþ b-cells, which probably explains their increased glucagon
expression26,27.
In previous studies, insulin and glucagon content, and/or islet
cell transcription factors have commonly been used to define
b-cell or a-cell identity. What constitutes a b-cell may be a matter
of semantics; nevertheless, our results raise the question of
whether transcription factor expression and insulin/glucagon
content are sufficient to define b-cell identity. In our mouse
model, b-cells (identified by lineage tracing) showed lower insulin
and increased glucagon content following 4 weeks of diabetes.
However, they maintained a partial b-cell identity; they expressed
Pdx1 and Glut2, and had Naþ channels characteristic of b-cells
(not a-cells).
Several studies have highlighted the remarkable plasticity of
islet cells. b-Cells can transdifferentiate into a-cells23,27–30.
Similarly, conversion of a-cells into b-cells following near-total
b-cell ablation has been observed31 and alterations in the
expression and activity of key b-cell transcription factors,
including Nkx6.1 (refs 32–35), FoxO1 (ref. 23) and Pdx-1 (ref.
35), are commonly observed following dedifferentiation or
transdifferentiation of islet cells. Chronic hyperglycaemia in
both diabetic rodent models and human type 2 diabetic islets can
also lead to changes in transcription factor expression and the
appearance of insþ /gluþ cells23,31,33–36. Our data consolidate
these findings by showing that hyperglycaemia per se can drive
alterations in islet cell identity.
A recent study of mice with an activating KATP channel
mutation (DN30-K185E) also found that hyperglycaemia led to a
dramatic loss of insulin content without marked changes in islet
cell death or proliferation37. They attributed this to b-cell
dedifferentiation due to upregulation of the islet progenitor
marker Ngn3. Although we found a similar increase in Ngn3
mRNA, we were unable to observe significant protein expression.
Wang et al.37 also reported a marked increase in glucagon
immunostaining but found few gluþ cells that were of b-cell
lineage. One possible reason for these differences may be that b-
cells from DN30-K185E mice might have dedifferentiated further
than those of bV59M mice, perhaps because of the higher blood
glucose level of DN30-K185E mice (433 versus 25mM). How
the severity and duration of hyperglycaemia affects b-cell
plasticity is currently unknown. Thus, we cannot exclude the
possibility that the changes we observe reflect an early inter-
mediary state in b-cell dedifferentiation or transdifferentiation to
a-cells. However, at this stage, their glucose transporters and
Naþ channels are more characteristic of b-cells than a-cells or
islet progenitor cells.
Our results suggest many of the changes we observed in islet
morphology and ultrastructure can be attributed to hyperglycae-
mia rather than KATP channel activation. Insulin therapy, which
normalizes blood glucose without affecting the open KATP channel,
prevented the changes in insulin- and glucagon-staining, b-cell
ultrastructure and number of insþ /gluþ cells produced by 4
weeks of diabetes. Furthermore, normalization of blood glucose by
glibenclamide following 4 weeks of diabetes reversed these changes,
suggesting that b-cell functional mass can be immediately restored
when blood glucose is controlled. This may explain why glucose-
induced insulin secretion is reinstated in patients with T2DM given
a low-calorie diet38. Although we cannot unequivocally distinguish
between the effects of hyperglycaemia and hypoinsulinaemia, the
fact that deletion of the insulin receptor in b-cells39 does not alter
their ultrastructure, or the relative proportions of insþ and gluþ
cells, favours the former possibility.
In conclusion, we show that chronic hyperglycaemia results in
the partial loss of b-cell identity in a mouse model of b-cell
dysfunction. Strikingly, these alterations are prevented and
reversed when blood glucose is normalized with anti-diabetic
drugs. This highlights the remarkable plasticity of b-cells and
their ability to reversibly alter their gene expression, structure and
function in response to changes in circulating glucose levels. Our
results also highlight the importance of good glucose control in
patients with diabetes and indicate that this should help preserve
b-cell structure and function, and may even reverse established
changes.
Methods
Generation of bV59M mice. All experiments were conducted in accordance with
the UK Animals Scientific Procedures Act (1986) and have been approved by the
University of Oxford DPAG local ethical committee. Mice hemizygously expressing
Kir6.2-V59M in insulin-secreting cells (bV59M mice) were generated using
a Cre-lox approach essentially as described12 but using an inducible rat insulin
promoter II (RIPII-Cre-ER mice40). Kir6.2-V59M expression was induced in 12-
to 14-week-old male and female mice by a single subcutaneous injection of 0.4ml
of 20mgml 1 tamoxifen in corn oil (Sigma). All experiments were performed
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in 12- to 14-week-old mice with a mixed (C3H, C57BL/6, 129/sv) genetic
background. Wild-type mice, RIPII-Cre-ER mice and mice expressing only the
floxed Kir6.2-V59M gene (ROSA) were used as controls. RosaRFPþ / mice were
produced as described41.
Molecular biology. Total RNA was prepared from isolated islets, amplified using
the Ovation Pico WTA System V2 (NuGen) kit and reversed transcribed. qPCR
was performed as described42 and transcript levels of Arx, Chop, Gfp, glucagon,
Glut2, insulin, MafA, MafB, Ngn3, Nkx6.1, Pax6, Pdx1 and Xbp1 spliced and three
reference genes (Actb, Hprt1 and Hspa8) quantified (for primer sequences see
Supplementary Table 1). Similar results were obtained when qPCR was performed
as described for FAC-sorted cells43.
In vivo physiology. After blood glucose levels had risen aboveB20mM (B2 days
after tamoxifen injection), animals were immediately implanted subcutaneously
with either a (1) placebo pellet, (2) 60-day slow-release glibenclamide pellet
(17mg kg 1 per day) (Innovative Research of America), or (3) two to three 30-day
(B0.1U per 24 h) insulin pellets (body weight o30 g, 2 pellets; 430 g, 3 pellets)
(LinShin Canada Inc.) under 2% isoflurane anaesthesia. Placebo pellets contained
vehicle but no drug. In separate experiments, Kir6.2-V59M expression was
induced, mice left diabetic for 4 weeks (blood glucose420mM), then treated with
glibenclamide (2-3 pellets; 34–95mg kg 1 per day), and studied 4 weeks later.
Free-fed plasma glucose levels were measured daily (at 1400 h; FreeStyle Lite
Blood Glucose Monitoring System, Abbott). Insulin and glucagon were measured
in plasma or whole islets by radioimmunoassay (Millipore and Euro Diagnostica,
respectively).
Electrophysiology. Islets were isolated and dispersed into single cells, as descri-
bed12. Single cells were cultured in 11mM glucose and patched within 2 days of
isolation. Naþ currents were recorded from cells within freshly isolated intact islets
using the standard whole-cell configuration as described44 and following infusion
with biocytin, cell identity confirmed by immunocytochemistry45. Macroscopic
KATP currents were recorded from cell-attached membrane patches on isolated
cells at  60mV, filtered at 5 kHz and digitized at 20 kHz12. Cell identity was
subsequently confirmed by immunocytochemistry.
Electron microscopy. Isolated islets were fixed in 4% paraformaldehyde and 0.5%
glutaraldehyde in phosphate buffer for 1 h, post-fixed in 1% osmium tetroxide,
block stained in 2% uranyl actetate, dehydrated in graded ethanol and embedded in
Spurr’s resin (Agar Scientific, Stansted, UK). Ultrathin sections (70 nm) were cut
onto Ni2þ grids, contrasted with 2% uranyl acetate and lead citrate, and examined
in a Jeol 1010 microscope (Welwyn Garden City, UK) with an accelerating voltage
of 80 kV.
b-Cell apoptosis was assessed from electron micrographs as the number of
b-cells with apoptotic nuclei (that is, displaying typical chromatin condensation):
b-cells (135–150 from n¼ 3–9 mice; n¼ 3 islets per mouse) were identified by the
presence of characteristic insulin granules.
Immunostaining and morphometric analysis. Immunostaining was performed as
described on fixed wax-embedded pancreatic sections12 and dispersed islet cells
were fixed within 2 h of isolation. For antibodies see Supplementary Table 2.
Insulin and glucagon area was analysed using the manual histology tool in Zeiss
LSM-510 software. Five pairs of 5-mm-thick serial sections, 100 mm apart were
analysed, for n¼ 3–6 animals of each genotype (B160 islets/mouse).
Flow cytometry. Pancreatic islet cell suspensions from b-RFP and bV59M-RFP
mice were separated by FAC sorting using a MoFlo Beckman Coulter Cytomation
sorter (Coulter Corp., Hialeah, FL). Islet populations were sorted immediately
following isolation into RNAse-free collection buffer for qPCR analysis as descri-
bed previously45. For Taqman probes, see Supplementary Table 3.
Statistics. Data are mean values±s.e.m. of the indicated number of experiments.
Significance was tested using One-way analysis of variance, Mann–Whitney Test
and Bonferroni post-hoc test applied as indicated.
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